This study focuses on testing a new drug called AMG 509 in adults with a type of prostate cancer that has spread and is resistant to standard treatment. This condition is known as metastatic castration-resistant prostate cancer (mCRPC). The main goal is to see how safe the drug is and to find out the best dose to use in future studies. Participants must have tried other treatments but not more than two types of a specific chemotherapy known as taxane.
- Study Length: Participants may need to stay involved for several weeks or months, depending on their response to the drug.
- Visits: Participants will need to visit the clinic regularly for monitoring and tests.
- Potential Benefits and Risks: The study offers a chance to try a new treatment, but there may be side effects or risks involved.
This study is not suitable for those with certain health conditions like small cell cancer of the prostate or untreated brain metastases. Before joining, discuss with your doctor to ensure this is the right choice for you.
How understandable was the trial content above?
Hard to understand
Easy to understand